Current Report Filing (8-k)
November 09 2016 - 04:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 9, 2016
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in
its charter)
Nevada
|
001-37854
|
99-0367049
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s name or former address,
if change since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
o
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02
|
Results of Operations and
Financial Condition
|
On November 9, 2016, Ekso Bionics Holdings,
Inc. (the “Company”)
reported its financial results for the quarter and nine
months ended September 30, 2016. The full text of the press release announcing such results is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
The
information contained in this report, including the information contained in Exhibit 99.1, is being furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation
language in such filing.
|
Item 9.01
|
Financial Statements and
Exhibits
|
(d) Exhibits
Number
|
|
Description
|
|
|
99.1
|
|
Press Release dated November 9, 2016.
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Maximilian Scheder-Bieschin
|
|
|
Name:
|
Maximilian Scheder-Bieschin
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
|
|
Dated: November 9, 2016
|
|
|
|
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2023 to Mar 2024